Literature DB >> 18756654

Glucosamine.

Stephen Dahmer1, Robert M Schiller.   

Abstract

Glucosamine is one of the most popular dietary supplements sold in the United States. Most clinical trials have focused on its use in osteoarthritis of the knee. The reported adverse effects have been relatively well studied and are generally uncommon and minor. No significant supplement-drug interactions involving glucosamine have been reported. The National Institutes of Health-sponsored Glucosamine/chondroitin Arthritis Intervention Trial, the largest randomized, double-blind, placebo-controlled study involving the supplement, still has not confirmed whether glucosamine is effective in the treatment of osteoarthritis. Despite conflicting results in studies, there is no clear evidence to recommend against its use. If physicians have patients who wish to try glucosamine, it would be reasonable to support a 60-day trial of glucosamine sulfate, especially in those at high risk of secondary effects from other accepted treatments. The decision to continue therapy can then be left to patients on an individual basis, while the physician monitors for possible adverse effects. Glucosamine should be used with caution in patients who have shellfish allergies or asthma, and in those taking diabetes medications or warfarin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756654

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Prevalence of Glucosamine and Omega-3 Fatty Acid Use and Characteristics of Users among Mid-Age Women: Analysis of a Nationally Representative Sample of 10,638 Women.

Authors:  D Sibbritt; C Lui; T Kroll; J Adams
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

2.  Effects of glucosamine sulfate and exercise therapy on serum leptin levels in patients with knee osteoarthritis: preliminary results of randomized controlled clinical trial.

Authors:  Dilek Durmus; Gamze Alayli; Yuksel Aliyazicioglu; Ozlem Buyukakıncak; Ferhan Canturk
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

3.  Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study.

Authors:  Jessie A Satia; Alyson Littman; Christopher G Slatore; Joseph A Galanko; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

4.  Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity.

Authors:  Rachel A Jones Lipinski; Yann Thillier; Christophe Morisseau; Christopher S Sebastiano; Brian C Smith; C Dennis Hall; Alan R Katritzky
Journal:  Chem Biol Drug Des       Date:  2021-05-28       Impact factor: 2.817

Review 5.  A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals.

Authors:  R R Simon; V Marks; A R Leeds; J W Anderson
Journal:  Diabetes Metab Res Rev       Date:  2010-12-07       Impact factor: 4.876

6.  Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids.

Authors:  Jörg Jerosch
Journal:  Int J Rheumatol       Date:  2011-08-02

Review 7.  A flood of health functional foods: what is to be recommended?

Authors:  Eun Sil Lee
Journal:  J Menopausal Med       Date:  2015-04-27

8.  Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling.

Authors:  Viktor Chesnokov; Chao Sun; Keiichi Itakura
Journal:  Cancer Cell Int       Date:  2009-09-10       Impact factor: 5.722

9.  A Study on Gentiana dahurica Fisch Ethanol Extract Alleviating Alcoholic Liver Disease in Mice: A Metabolomic Analysis of the Liver.

Authors:  Houkang Cao; Yanxiu Guo; Ling Jin
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-29       Impact factor: 2.629

10.  Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older.

Authors:  David Sibbritt; Jon Adams; Chi-Wai Lui; Alex Broom; Jonathan Wardle
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.